ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2024
Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024.
Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 102 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
102 citing papers in PubMed, 3 syntheses or guidelines pooled it, 165 citations in OpenAlex.
- Pooled it
- Nirsevimab for preventing respiratory syncytial virus lower respiratory tract infections in infants: a systematic review and meta-analysis.Frontiers in public health · 2025Pooled it
- Evaluating the efficacy, safety, and immunogenicity of FDA-approved RSV vaccines: a systematic review of Arexvy, Abrysvo, and mResvia.Frontiers in immunology · 2025Pooled it
- Lower Respiratory Tract Infections Following Respiratory Syncytial Virus Monoclonal Antibody Nirsevimab Immunization Versus Placebo: Analysis From a Phase 3 Randomized Clinical Trial (MELODY).Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Trial
- Strategies used to improve immunization coverage of nirsevimab in an autonomous community in Spain.Human vaccines & immunotherapeutics · 2026Article
- Acute viral bronchiolitis before and after implementation ofThe Lancet regional health. Europe · 2026Article
- Observational
- Respiratory Pathogen Co-Detection in Hospitalized Infants with Bronchiolitis and Implementation of Universal Nirsevimab Immunoprophylaxis: A Six-Year Observational Study.Children (Basel, Switzerland) · 2026Article
- Review
- Respiratory Syncytial Virus-Related Hospitalizations Among Infants Receiving Nirsevimab.JAMA network open · 2026Article
- Review
- Nirsevimab Immunization to Prevent Pediatric RSV Hospitalizations.JAMA pediatrics · 2026Observational
- Article
- Cost-Effectiveness of Immunising Interventions to Reduce Respiratory Syncytial Virus Disease Burden in Infants in Australia.PharmacoEconomics · 2026Article
- Virus Detection and Hospitalization Rate in Infants With Bronchiolitis After Nirsevimab Introduction: A Retrospective Comparative Two-Season Study.Pediatric pulmonology · 2026Article
- Real-world effectiveness of nirsevimab against RSV hospitalisation in infants during a season with low coverage and delayed circulation in Beijing, China: a population-based retrospective cohort study.The Lancet regional health. Western Pacific · 2026Article
- Protease-mediated PRC1 dissociation promotes H2AK119ub remodeling during stress responses.The EMBO journal · 2026Article
- The Impact of Nirsevimab on the Transport of Critically Ill Children.Children (Basel, Switzerland) · 2026Article
- Article
- Respiratory syncytial virus epidemiology and effectiveness of infant nirsevimab: 2024 results from the Australian Sentinel Hospital Network (FluCAN-PAEDS).Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2026Article
42 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors at 12 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The monoclonal antibody nirsevimab was at least 70% effective in preventing hospitalisations in infants with lower respiratory tract infections (LRTI) positive for respiratory syncytial virus (RSV) in Spain (Oct 2023-Jan 2024), where a universal immunisation programme began late September (coverage range: 79-99%). High protection was confirmed by two methodological designs (screening and test-negative) in a multicentre active surveillance in nine hospitals in three regions. No protection against RSV-negative LRTI-hospitalisations was shown. These interim results could guide public-health decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.